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Abstract 
While determining the roles that different functional domains of Abelson tyrosine kinase 
(Abl), a key developmental regulator and oncogene, during normal development, our lab was 
surprised to find that a short, conserved motif (PXXP) in the linker region was more important 
for Abl’s morphogenic roles than both kinase activity and F-actin binding. This finding led us to 
hypothesize that Crk binding to Abl’s PXXP motif is critical for mediating Abl’s developmental 
functions. Crk family proteins, including Crk and Crk-like (Crk-L), are a well-conserved family 
of small adaptor proteins that play a role in cell adhesion, migration, and other biological 
processes during normal development. Crk also plays a role in various cancers, including 
invasive bladder cancer, and Crk-L is a key mediator of oncogenic forms of Abelson tyrosine 
kinase (Abl) in Leukemia. Based on Abl’s well-defined roles in central nervous system (CNS) 
patterning, we hypothesized that Crk might be required for proper CNS patterning. To test this 
hypothesis, I used RNAi to deplete Crk both maternally and zygotically in embryos and asked 
what effect, if any, this had on embryonic viability and CNS patterning. Using this approach, I 
found that Crk is required for embryonic viability and that loss of Crk results in CNS patterning 
defects. To better understand the mechanism(s) by which Crk may alter CNS patterning, I am 
looking at the Robo/Slit repulsive axon guidance cues in the Crk knock down embryos to 
determine if the CNS patterning defects observed are the result of loss of Crk affecting this 
pathway. I found that localization of these proteins remains largely normal and their function 
appears unaltered, indicating that this pathway is intact and does not require Crk. Preliminary 
analysis suggests that zygotic loss of crk also results in partially penetrant CNS patterning 
defects, mimicking what we see using an RNAi approach. We are continuing to characterize 
morphogenic defects associated with loss of Crk to determine its Abl-dependent and –
independent roles. This work will help provide better insight into Crk’s roles during normal 
development and disease states. 
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I. Introduction 
Development and tissue homeostasis require tight coordination of cell adhesion with 
actin remodeling to allow cells to change shape and migrate. Both processes require the 
assembly and activity of multi-protein signaling complexes, which include small adaptor 
proteins1. Crk family proteins, including Crk and Crk-like (Crk-L), are a well-conserved family 
of small adaptor proteins that play a role in cell adhesion, cell migration, and other biological 
processes during normal development2. The mammalian Crk family is comprised of three 
proteins-- Crk I, Crk II and Crk-L-- expressed from two gene loci3. crk is alternatively spliced 
into crk I (minor form) and crk II (predominant form), while crk-L produces a single isoform3. 
Crk proteins include a Src Homology 2 (SH2) domain and either one or two Src Homology 3 
(SH3) domains connected by linker sequences1,3 (Fig. 1). Their SH2 domain allows for 
interactions with upstream binding partners such as phosphorylated receptor tyrosine kinases and 
focal adhesion complexes, while their SH3 domains mediate downstream interactions, typically 
with effector molecules or other adaptor proteins4. Both upstream and downstream interactions 
are controlled by phospho-regulation by tyrosine kinases, including Abelson tyrosine kinase 
(Abl)3,5,6,7. Both Crk and Crk-L also play 
critical roles in development and cancer. 
Crk drives epithelial-to-mesenchymal 
transitions in normal development, and is 
overexpressed in many cancers, including 
breast, ovarian, and bladder cancers, while 
Crk-L is a key mediator of oncogenic forms 
of Abl in Leukemia6-11.   
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Figure 1. Crk is highly conserved between mammals and Drosophila.  
Regulatory phosphorylation sites indicated by Ys (e.g. Y221). 
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Crk I, Crk II, and Crk-L in mammals have many overlapping functions due to the 
conserved structure and functional domains between the proteins. This redundancy makes it 
difficult to study Crk function in mammals and cultured cells, because all three gene products 
would have to be knocked down to demonstrate complete loss-of-function phenotypes12. 
Knockout mouse models for Crk or Crk-L both die embryonically, but with different 
developmental defects, indicating that the different gene products also have distinct, non-
overlapping roles13-17. As of yet, no double knockout has been conducted in mice. Drosophila 
melanogaster has only one crk gene, resulting in one Crk protein, and thus is ideal for studying 
the conserved function of Crk family proteins18. 
While determining the roles that different functional domains of Abelson tyrosine kinase 
(Abl), a key developmental regulator and oncogene, play during normal development, our lab 
was surprised to find that a short, conserved motif (PXXP) in the linker region was more 
important for Abl’s morphogenic roles than both kinase activity and F-actin binding in certain 
contexts19. In mammals three proteins are known to bind Abl’s PXXP motif—Abi20,21, Crk22, and 
Nck22—suggesting they may play a crucial role in Abl’s function during morphogenesis. Of 
these three proteins, we wanted to know which, if any, work with Abl or are essential for Abl 
function during morphogenesis. I used RNAi to knockdown abi, crk, or nck expression, and ask 
if this resulted in phenotypes similar to maternal/zygotic Abl loss.  Reducing abi or crk results in 
increased embryonic lethality similar to Abl loss, while nck knockdown does not (Fig. 3). Given 
that little is known about Crk function in Drosophila and Crk-L is the major downstream 
mediator of oncogenic effects of BCR-Abl, we decided to focus in on Crk. We hypothesized that 
Crk binding to Abl’s PXXP motif is critical for mediating Abl’s developmental effects. Based on 
Abl’s well-defined roles in central nervous system patterning19,23, I specifically focused on 
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whether Crk is required for proper CNS patterning and, if so, on more extensively characterizing 
Crk’s role in CNS patterning. 
II. Methods 
Fly stocks used 
All stocks were maintained at on standard cornmeal agar media at room temperature or 
25°C. All RNAi crosses were maintained at 25°C. 
The following stocks, obtained from the Bloomington Drosophila Stock Center (NIH 
P400D018537), were used in this study:  
y1, sc*, v1; P{y+t7.7 v+t1.8=TRiP.HMC03964}attP40 (crk HMC RNAi);  
y1, sc*, v1; P{y+t7.7 v+t1.8=TRiP.HMS01597}attP2 (abi RNAi);  
 
y1, v1; P{y+t7.7 v+t1.8=TRiP.GL01519}attP2/TM3, Sb1 (nck RNAi)  
We obtained y1, sc* v1; P{y+t7.7 v+t1.8=TRiP.HMJ2295}attP40/CyO (crk HMJ RNAi) from 
the National Institute of Genetics (Mishima, Japan). 
Additional stocks used include y,w (used as our wild-type laboratory strain); and w; 
P(mat-tub-Gal4)mat67; P(mat-tub-Gal4)mat15 (subsequently referred to as matII; matIII); and 
w; elav-Gal4/CyO. 
RNAi experiments 
 For all RNAi experiments, except CNS-specific knockdown, we wanted to knockdown 
both maternal and zygotic mRNA and protein, as described by Staller et al24 (summarized in Fig. 
2). To do so, we generated mothers carrying two copies of a strong, maternally contributed 
GAL4 (matII; matIII) and a single copy of the UAS-shRNA targeting the transcript of interest. In 
general, the genotype of the mothers used in the RNAi experiments was: 
!"#!!!!"# !"#$%!&'$ !"#$%&"'(! !" !"#$%$&#!"#$$ ;!"#$$$!  
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We then crossed virgins of this 
genotype to males carrying zero, one, or 
two copies of the UAS-shRNA targeting 
the transcript of interest, depending on 
whether the insert was homozygous 
viable. Using this approach, all embryos 
had reduced maternal contribution of the 
transcript of interest. Additionally, we 
were able to alter the level of zygotic 
knockdown by varying the number of 
copies of UAS-shRNA present.  
Measuring embryonic viability 
To measure embryonic viability, crosses were set up in cups and allowed to lay eggs on 
apple juice agar plates overnight (16-24 hours) at 25°C. Individual embryos were then 
transferred to new plates, and the total number of embryos recorded (~200 embryos/individual 
experiment). After forty-eight hours at 25°C, the number of embryos that have hatched and the 
number of embryos that did not hatch were recorded. Embryos are expected to hatch after 24 
hours, so after 48 hours, any eggs that have not hatched are considered dead. Percent viability 
was then determined by dividing the number of embryos that hatched by the total number of 
embryos placed on the plate. An un-popped cuticle prep was done on any unhatched eggs to 
determine how many were unfertilized and the percent viability was adjusted accordingly. 
 
 
Figure 2. Strategies for knockdown of maternal and 
zygotic transcripts. (A) Depletion of a maternal 
transcript following expression of shRNAs in the 
female germline. The maternal Gal4 driver (blue) 
activates shRNAs (red), which deplete target transcripts 
(green). (B) Depletion of a zygotic transcript by 
loading the embryo with maternally derived shRNAs. 
(C) Depletion of a zygotic transcript following zygotic 
activation of shRNAs by maternally loaded Gal4 
protein. (Staller et al. 2013) 
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Confocal microscopy of Central Nervous System 
Embryos were dechorionated in 50% bleach for 5 minutes at room temperature. They 
were then fixed in 1:1 4% formaldehyde:heptane for 20 minutes at room temperature and the 
vitelline membrane removed by shaking embryos in 1:1 methanol:heptane. The embryos were 
then rinsed three times in phosphate buffered saline (PBS) containing 0.1% Triton-X100 (PBT), 
and blocked by incubating in PBT containing 1% normal goat serum (PNT) for 30 minutes at 
room temperature. They were then incubated in primary antibody diluted in PNT either at room 
temperature for 4 hours or overnight at 4°C. Following washing three times with PBT, embryos 
were incubated in secondary antibody diluted in PNT either at room temperature for 2 hours or 
overnight at 4°C.  
Primary antibodies used were anti-BP102 (1:200), anti-FasII (1:100), anti-robo (1:100), 
and anti-slit (1:10) and were obtained from the Developmental Studies Hybridoma Bank, created 
by the NICHD of the NIF and maintained at the University of Iowa, Department of Biology, 
Iowa City, IA, 52242. Secondary antibodies used were anti-mouse immunoglobulin G2a 
(IgG2a), anti-mouse immunoglobulin G2b (IgG2b), anti-mouse immunoglobulin G1 (IgG1), and 
anti-rat IgG conjugated to Alexa Fluor (AF) 488, AF568, or AF647 as indicated. The embryos 
were mounted on glass slides in Aqua-Poly/Mount (Polysciences) and imaged on a Zeiss LSM-5 
PASCAL confocal microscope. Images were processed using ImageJ25. 
III. Results 
Based on our lab’s finding that the PXXP motif within conserved region 1 (CR1) is more 
essential for morphogenesis than both kinase activity and F-acting binding19, we wanted to look 
at which of Abl’s PXXP-binding partners are required during embryonic morphogenesis. In 
mammals, it is known that three SH3 domain containing proteins, Abi20,21, Crk22, and Nck22, 
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interact with Abl via this conserved PXXP motif. To 
determine if any of these PXXP-binding partners is 
essential for embryonic morphogenesis, I conducted a first 
pass RNAi screen that should allow us to knockdown both 
maternal and zygotic mRNA and protein levels. In wild-
type flies, it is not unusual for up to 10% to die 
embryonically (in our wild-type control, 5.5% died, Fig. 3). The knockdown of nck resulted in 
5.5% lethality, identical to the wild-type control (Fig. 3), though we did not determine if nck 
RNAi effectively reduced Nck protein levels. Consequently, we decided not to continue further 
with nck. In contrast, crk RNAi (HMC03964) showed a lethality of 87%, while abi RNAi 
showed a lethality of 99% (Fig. 3). Here, I am focused on the effects of loss of crk on embryonic 
morphogenesis.   
Because of its location on the 4th chromosome, we lacked many of the sophisticated 
genetic tools that would allow us to generate embryos lacking both maternal and zygotic crk. 
There was only one extant crk 
allele (crkKG00336; a P-element 
insertion between the 
transcription start site and start 
codon), and it has not been fully 
characterized. Because of this 
limitation, we initially relied on 
transgenic RNAi lines to reduce 
maternal and zygotic crk levels. I 
Figure 3: A first pass RNAi-based screen revealed 
that reduction of abi or crk severely reduced larval 
viability, while nck had no effect on viability.  
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Figure 4. crk HMC RNAi results in strong embryonic lethality, while crk HMJ RNAi 
also results in significant, albeit weaker, embryonic lethality. 
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used two crk RNAi lines- HMC03964 (from here on 
known as crk HMC RNAi) and HMJ2995 (from 
here on known as crk HMJ RNAi), each of which 
targets a different region of the crk transcript, to 
ensure the phenotypes I observed were caused by 
knockdown of crk and not the result of non-specific 
off-target effects.   
The controls used for viability experiments 
carried the RNAi construct for the respective RNAi 
lines, but did not have the Mat-GAL4, so the RNAi 
was not produced. The HMC control and HMJ 
control result in 97.9% viability and 97.5% viability, respectively (Fig. 4), which is unchanged 
from wildtype where up to 10% die embryonically. Using the crk HMC RNAi line to deplete 
maternal/zygotic crk strongly reduces embryonic viability. Crossing 
!"#!!"#!"#$% (!"# !"#$)!"#$$ ;!"#$$$!  virgins to males that are heterozygous for the crk RNAi 
(HMC03964) decreases viability to 6.1%, while crossing these virgins to crk RNAi homozygous 
males further reduces viability to 1.1% (Fig. 4).  Using the second crk HMJ RNAi line, I 
observed 72.3% embryonic viability, which is decreased from wildtype, but less severe than the 
HMC line (Fig. 4). This compares to 9.4% viability in maternal/zygotic loss of abl19. 
To ensure this increase in lethality compared to wild-type is the result of knockdown of 
Crk protein levels, we conducted a Western blot to measure Crk protein levels in both RNAi 
lines. The HMC line virtually eliminates Crk, while the HMJ line substantially reduces it (Fig. 
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Figure 5. Both RNAi lines result in strong 
knockdown of crk protein, but to different degrees.  
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5). This demonstrates that both 
RNAi lines result in decreased 
levels of crk, but to different 
extents, which may explain the 
observed differences in 
lethality. 
Using these RNAi 
reagents, I next looked at Crk’s 
role in central nervous system 
(CNS) patterning to compare 
its role with Abl’s well-defined role in CNS patterning19,23. I used antibodies against BP102, 
which labels all CNS axons26, and FasII, which labels a subset of axons in the longitudinal axon 
bundles27,28. The crk HMC RNAi line results in severely disrupted CNS patterning, similar to 
70% of ablΔCR1 mutants and the milder phenotypes seen in 44% of abl null mutants (Fig. 6B 
compared to 6C-D and Fig. 7). This similar phenotype, in which longitudinal axons form (albeit 
wildtype crk RNAi 
Central nervous system axons 
abl 
MZ
  severe mild 
Figure 6. crk RNAi results in CNS patterning defects similar to the minor class of 
mild phenotypes seen in of abl maternal/zygotic mutants or upon deletion of CR1. (A) 
wildtype. (B) crk RNAi (HMC03964). (C) abl with a deletion of the CR1 region 
(AblΔCR1), (D-E) abl maternal/zygotic mutants. Wild-type central nervous systems 
exhibit a ladder-like appearance with longitudinal axon bundles making up the sides and 
commissural axon bundles making up the rungs (A). crk RNAi results in a range of 
phenotypes, including disorganized longitudinal axon bundles and failure to form 
commissural axon bundles (B). AblΔCR1 mutants fail to form commissural axon bundles, 
though the longitudinal axon bundles appear to form normally (C). ablMZ exhibit a less 
frequently observed, milder phenotype with disorganized longitudinal axons bundles and 
no commissural axon bundles (D), but the more frequent phenotype exhibits a severely 
disrupted CNS (E). (Panels A, C, D, and E reproduced from Rogers et al. 2016) 
A B C D E 
Figure 7. Loss of Crk results in Central Nervous Systerm (CNS) patterning defects. (A) 
Embryos of indicated genotype stained with antibodies against BP102 (green in left panels) and 
FasII (red in left panels, white in right panels). (B) Quantification of severity and penetrance of 
observed CNS patterning defects. Most HMJ RNAi embryos exhibit wild-type CNS patterning 
(B-blue) or a variety of minor CNS defects, including small gaps and incorrect midline crossing 
(center panels, B-orange). Most HMC RNAi embryos demonstrate severe CNS patterning 
defects (right panels, B-gray). 
A B 
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abnormally) and the commissural axons fail to form entirely, is more mild when compared to the 
severe CNS patterning phenotypes seen in 56% of maternal and zygotic abl mutants (Fig. 6C 
compared to 6E).  
The crk HMC RNAi line most commonly results in severely disrupted CNS patterning 
(85%), with many embryos lacking commissural axon formation and with abnormal longitudinal 
axons (Fig. 7). A minority of crk HMC RNAi embryos (15%) develop minor CNS patterning 
defects or have wild-type CNS patterning (Fig. 7). The crk HMJ RNAi line results in more mild 
defects in CNS patterning (35% abnormal), mostly incorrect midline crossings, but also 
including loss of commissures and small breaks in the longitudinal axon bundles of the ventral 
nerve cord (Fig. 7). A small percentage (5%) of HMJ RNAi embryos exhibit severe CNS 
patterning. However, the majority (55%) develop wild-type CNS patterning (Fig. 7). Despite the 
difference in phenotype, the RNAi lines are consistent in that they both result in embryonic 
lethality and affect CNS patterning, indicating that the defects are likely due to crk knockdown 
as opposed to off-target effects in one of the RNAi lines. 
Because the one extant crk mutant (crkKG00336)29 is a P-element insertion and has not been 
fully characterized, we sought to create a null allele using CRISPR. In addition to deleting the 
entire crk locus, this approach allowed us to incorporate an attP landing site, so we can target 
rescue constructs back into the genomic locus, thereby conferring endogenous regulation of these 
rescue constructs, including fluorescent protein tagged and FRT-flanked versions.  We have 
recently begun characterizing this mutant (crk
ΔattP
), using the approaches we used with the RNAi 
lines. We never see crk
ΔattP
/crk
ΔattP
 adults, which suggests homozygous loss of crk is lethal. To 
maintain this allele as a stock, we put it over a GFP-marked inverted fourth chromosome (In(4) 
ciDciDpanciD) that is also homozygous lethal. To define the lethal period for the homozygous 
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crk
ΔattP
mutants, we first assessed embryonic viability of this stock. Because homozygosity for the 
In(4) ciDciDpanciD chromosome is lethal, our base-line viability will be 75% as 25% of the 
embryos will die from homozygosity of In(4) ciDciDpanciD (Fig. 8A, dotted red line). If the 
crk
ΔattP
 mutation is embryonic lethal, we would expect 25% of the embryos to die from 
homozygosity of crk
ΔattP
. However in this assay, we observe only 35% embryonic lethality as 
opposed to the 50% we would expect if crk
ΔattP
 mutants are embryonically inviable, indicating 
that at least some, if not all, of the homozygous crk mutants survived embryogenesis (Fig. 8A).  
Next, we measured pupal lethality; percent viability was determined by dividing the number of 
adults that eclose by the total number of pupae that formed on the sides of the vial. Pupal 
lethality experiments were done using crk
ΔattP
 heterozygotes (over a true wildtype chromosome) 
crossed to themselves, so we would expect 25% to be wild-type, 50% to be heterozygotes, and 
25% to be crk
ΔattP
 homozygotes. Here we observed that 25% of the pupae die, which corresponds 
to the expected fraction that would be homozygous for crk
ΔattP
 (Fig. 8B). This suggests that 
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Figure 8. crk
ΔattP
 zygotic mutants do not die embryonically, but do exhibit pupal lethality. (A) Quantification of 
embryonic viability. The GFP-marked inverted fourth chromosome (In(4) ciDciDpanciD) is homozygous lethal, so the 
expected baseline embryonic viability is 75% (red dotted line). Embryonic viability of crk
ΔattP
 zygotic mutants was 65%. (B) 
Quantification of pupal viability. Pupal viability of crk
ΔattP
 zygotic mutants was 75%. 
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crk
ΔattP
 homozygotes primarily die as pupae, similar to abl zygotic mutants30.  
Because of the CNS patterning phenotype observed in the crk RNAi embryos, I next 
asked if crk
ΔattP
 mutants also exhibit CNS patterning defects. Here, I was able to distinguish 
crk
ΔattP
 heterozygotes from crk
ΔattP
 homozygotes using a homozygous lethal, GFP marked fourth 
chromosome (P{w[+mC]=ActGFP}unc-13[GJ]). Using this strategy, crk
ΔattP
 homozygotes are 
readily identified by the absence of GFP. Preliminary examination of these embryos shows that, 
while CNS patterning in crk
ΔattP
 heterozygotes and the majority (81%, n=17) of crk
ΔattP
 
homozygotes appear normal (Fig. 9A), homozygous mutants exhibit partially penetrant CNS 
phenotypes (Fig. 9 B, C). Some embryos (6%, n=17) show defects similar to the more mild 
defects seen when using crk RNAi line HMJ2995, including inappropriate midline crossing or 
small breaks (Fig. 9). However, 12% (n=17) of embryos showed much more severe defects that 
resembled the stronger crk RNAi line (HMC03964) or abl maternal zygotic mutants (Fig. 9).  
The CNS phenotypes seen in both RNAi lines and our crk deletion mutant led us to ask 
how Crk is participating in CNS patterning. During the development of the CNS, axons extend 
Figure 9. Heterozygotes for the crk deletion exhibit wild-type central nervous systems, while homozygotes for the deletion show 
partially penetrant CNS phenotypes. Embryos of the indicated genotype stained with antibodies against BP102 (green, A’-C’) and FasII 
(red, A”-C”). crk
ΔattP
 heterozygotes exhibit normal CNS patterning (A-A”). crk
ΔattP
 homozygotes show minor CNS defects, such as 
inappropriate midline crossing (B-B”), while some embryos exhibit severely disrupted CNS patterning (C-C”). 
  
A B C A’ A” B’ B” C” C’ 
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from the cell bodies along 
either side of the 
longitudinal tracks, and 
either remain on the 
ipsilateral side and extend 
longitudinally or cross the 
midline and extend along the 
contralateral tract31. 
Mediating this decision are a number of attractive and repulsive guidance cues along the midline, 
which direct the axons to cross in certain places31.  We started by asking whether Crk localizes to 
the CNS, using a rescue construct tagged with monomeric Neon Green and a 3XFLAG tag 
(mNG-3XFLAG-Crk), which is expressed from the endogenous locus. Using this line, we looked 
at Crk localization in the CNS and found that Crk was enriched in axons and in cells at the 
midline (Fig. 10- yellow arrows, presumably midline glia). The presence of Crk in axons 
indicates that it is in the right location and cell type to participate in interpretation of axon 
guidance cues.  
I am currently looking at one type of axon guidance cue, a repulsive midline cue 
mediated by the interaction between Slit (a repulsive ligand) and Robo (its receptor)32, to 
determine if Crk plays a role in this signaling pathway. Previous work by other groups has 
shown that Abl works downstream of Robo to negatively regulate Slit/Robo signaling33. Based 
on these findings and our hypothesis that Crk may work with Abl to regulate CNS patterning, we 
would expect Crk to also act downstream of Robo. However, given that Robo is also a substrate 
for Abl kinase activity33, I sought to rule out the possibility that Crk could work upstream of 
Figure 10. Endogenously tagged Crk shows that Crk in enriched in axons and cells at the  
midline. mNG-3XFLAG-Crk embryos with tagged Crk (green A, A”) and stained for BP102 (red  
A, A’). These embryos show localization of endogenous Crk in the embryonic CNS.  Crk is  
enriched in axons and in cells at the midline (A”, yellow arrows). 
A” A’ A 
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Robo to regulate Robo or Slit localization by asking if Robo and Slit localization is altered by 
loss of Crk.  
In wildtype embryos, Robo is restricted to the longitudinal axons, which do not cross the 
midline (Fig. 11A-A”). In 16/17 crk HMC RNAi embryos, where we get the strongest CNS 
phenotypes, Robo restriction and enrichment in longitudinal axons is unchanged (Fig. 11B-C”), 
suggesting that Crk is not required for proper localization of Robo within the CNS. I next wanted 
to ask whether loss of Crk had any effect on localization of Robo’s ligand, Slit. In wildtype, Slit 
is localized at the midline where it is secreted by midline glia (Fig. 11D-D”). In crk HMC RNAi 
embryos, Slit localization to the midline is also largely normal, although I do observe minor 
Figure 11. Robo localization in the crk HMC RNAi line is similar to that in wildtype embryos, and while Slit localization is largely 
normal, there are some midline disruptions. (A-C) Embryos stained with BP102 (green, A’-C’) and Robo (red, A”-C”). Wild-type 
embryos show Robo is enriched in the longitudinal axons (A-A”). Robo in HMC RNAi embryos is localized to the longitudinal axons that do 
form, albeit abnormally (B-C”). (D-F) Embryos stained with BP102 (green, D’-F’) and Slit (red, D”-F”). Slit in HMC RNAi embryos 
localizes primarily to cells at the midline, but Slit is also found in some cells outside the midline (E-F, yellow arrows). These abnormal 
localizations of Slit correspond with strong repulsion of axon bundles (E-F, arrows). 
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midline disruptions in 7/11 embryos (Fig. 11E-F”). This suggests that Crk is largely dispensable 
for proper Slit localization. Interestingly, where I observe midline disruptions causing Slit to be 
misplaced, I observed strong repulsion of axon bundles (arrows, Fig. 11E-F”), suggesting that 
Slit-Robo- mediated repulsive signaling is intact and does not require Crk.  
Next, I attempted central nervous system- specific knockdown of Crk using a GAL4 
driver expressed in neurons, elav-GAL4, crossed to the crk HMC RNAi line or the crk HMJ 
RNAi line. Embryos from both crosses exhibited central nervous systems with no noticeable 
defects (data not shown). I also used an overexpression construct crossed to elav-GAL4 to 
overexpress Crk in a CNS-specific manner. This also resulted in embryos with wild-type central 
nervous systems (data not shown). Since Crk knockdown or overexpression in the axons did not 
show an obvious phenotype, I began to look at whether the CNS phenotypes seen in Crk 
knockdown embryos might be the result of Crk depletion in midline cells. I used slit-Gal4 to 
deplete Crk in midline cells, which did not show an increase in embryonic lethality compared to 
wildtype (data not shown). However, with tissue-specific knockdown, we have no way of 
determining if Crk protein levels are actually reduced in that tissue, which could explain the lack 
of noticeable phenotype. It is also possible that the knockdown achieved using this strategy is 
occurring too late in morphogenesis to have an effect on CNS patterning. 
IV. Discussion 
Studies in cell culture and in mouse mutants suggest Crk is essential for cell adhesion, 
cell migration, and other biological processes during normal development4. Loss of Crk can 
result in disruption of these processes leading to developmental defects or cancer6-10. By 
understanding how Crk works, both in normal development and in disease states, we can begin 
to understand what specifically causes these disease states and how we might go about fixing 
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them. We started studying Crk after our lab’s work on Abl revealed that Abl’s CR1, which 
contains a conserved PXXP motif, is more essential for some aspects of development than both 
the F-actin binding domain and kinase activity19. This finding led us to focus on better 
understanding the role of Abl’s PXXP-binding partners during morphogenesis. 
I screened three known CR1 binding partners in mammals, Abi20,21, Nck22, and Crk22, for 
embryonic lethality and found that knockdown of abi and crk, but not nck, results in strong 
embryonic lethality. nck knockdown resulted in 5.5% lethality (same as wild-type control), 
whereas abi RNAi showed 99% lethality and crk RNAi showed 87% lethality. The efficacy of 
the nck RNAi line in reducing nck transcript levels was not assessed, so we cannot rule out the 
possibility that Nck has a role here. Given that little is known about Crk function in Drosophila 
and Crk-L is the major downstream mediator of oncogenic effects of BCR-Abl, we decided to 
focus on Crk’s roles in development, working with and independently of Abl. To study crk 
function I have used two crk RNAi lines and a crk null allele we recently developed using 
CRISPR.  
The broadest assessment of phenotype is measuring lethality caused by knockdown of the 
protein, so I started there. The first crk RNAi line (TRiP line HMC03964) exhibited an 
embryonic lethality of 93.9% when crossed to males carrying one copy of the RNAi and 98.9% 
when crossed to males with two copies of the RNAi. To check for off-target effects, I also 
looked at a second crk RNAi line (TRiP line HMJ2995), which shows a lower, but still elevated, 
embryonic lethality of 26.7%. Western data showed that the crk HMC line virtually eliminates 
Crk, while the crk HMJ line substantially reduces it, but does not completely eliminate it, which 
may explain the difference in lethality. Our zygotic crk CRISPR mutants (crk
ΔattP
) did not show a 
significant embryonic lethality, but were found to die later, in the pupal stages. This is different 
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from the crk RNAi lines, indicating maternal contribution of crk is sufficient for embryonic 
development, but not for survival to adulthood. We are currently also eliminating maternal 
contribution by generating germline clones using a FLPout strategy34 with our crk
ΔattP
allele that 
will allow us further assess how complete elimination of Crk affects embryogenesis. 
Based on Abl’s well-defined role in CNS patterning19,24, I next asked if Crk has a role in 
CNS patterning by looking at the CNS of crk RNAi embryos and crk
ΔattP
homozygotes. The crk 
HMC RNAi line shows CNS patterning defects where the longitudinal axons form abnormally, 
and the commissural axons do not form at all. This is similar to the phenotype of AblΔCR1 
mutants or the less frequent, milder phenotypic class observed in abl maternal/zygotic mutants. 
The weaker crk HMJ RNAi line shows less severe CNS patterning defects where the CNS has 
only small gaps or breaks or inappropriate midline crosses, resembling similar phenotypes seen 
in abl zygotic mutants. The similarity of phenotypes (though not of severity) between the two 
RNAi lines suggests that knockdown of crk is the cause of these phenotypes and they are likely 
not the result of off-target effects. Preliminary examination of crk
ΔattP
 mutants shows phenotypes 
more similar to the weaker crk RNAi line (small breaks and midline crosses); however, some 
mutants exhibit severe CNS patterning defects similar to loss of Abl or deletion of CR1. The 
similarity of these phenotypes to those of maternal/zygotic loss of abl suggests Crk and Abl may 
be working together to modulate cell behavior during CNS patterning. However, more data is 
needed to more definitively characterize the CNS patterning phenotypes seen in these animals. 
Maternal contribution of crk in crk
ΔattP
 zygotic mutants may mask the defects caused by loss of 
crk, so it would be helpful to look at CNS patterning after eliminating maternal contribution in 
these mutants, where we would expect to see stronger phenotypes. However, preliminary 
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examination of embryos lacking maternal contribution of Crk shows severe developmental 
defects that result in severe disruption of the embryos before the CNS begins to develop. 
I next asked how Crk is mechanistically affecting CNS patterning during development. 
During the development of the CNS, axons either remain on the ipsilateral side of the CNS and 
extend longitudinally or cross the midline and extend along the contralateral tract, a decision that 
is mediated by a number of attractive and repulsive guidance cues. Using an endogenous rescue 
construct tagged at the N-terminus with monomeric Neon Green and a 3XFLAG tag (mNG-
3XFLAG-Crk), we were able to look at Crk localization in the CNS. We found that Crk localizes 
both to the axons and to cells at the midline (presumably midline glia), which indicates that Crk 
is in the right location to potentially play a role in axon guidance decision making. I am currently 
asking if one of these midline guidance cues, a repulsive cue mediated by the interaction between 
Slit and its receptor Robo, is altered by loss of Crk. Robo localization in the crk HMC line 
appears to be normal, restricted to the longitudinal axons. Slit localization is also largely normal 
with Slit localized to the midline, but does demonstrate some midline disruptions. These 
disruptions correspond with strong axon bundle repulsion, indicating that Slit-Robo signaling is 
likely intact, and that Crk is not required to mediate Slit/Robo-dependent repulsive guidance at 
the midline. I am currently collecting more data to more definitively characterize these 
phenotypes. Future work will need to be done to assess whether loss of Crk alters localization or 
function of mediators of additional repulsive axon guidance cues as well as attractive axon 
guidance cues at the midline.  
To further assess this, we attempted to knock down crk in a CNS-specific manner, which 
showed no effect on CNS patterning (data not shown). Overexpression of crk in a CNS-specific 
manner also exhibited no noticeable CNS patterning defects (data not shown). Additionally, 
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knock down of Crk in midline cells did not result in an increase in embryonic lethality, but the 
CNS patterning in these embryos has yet to be observed. However, we are unable to definitively 
determine if Crk levels are reduced in these specific tissues, so the lack of phenotype observed 
may be the result of insufficient knockdown or reduction of Crk too late in development to have 
an effect. 
We are also continuing to characterize the effects of loss of crk on overall morphogenesis 
as well as what role crk plays in other developmental events in Drosophila. We have developed a 
number of rescue constructs to be incorporated into our crk deletion mutant and are working to 
characterize and quantify their ability to rescue loss of crk. Additionally, we are using the mNG-
3XFLAG-Crk rescue construct to look at Crk localization throughout the embryo during various 
stages of morphogenesis. We also plan to assess how phenotypes seen upon loss of Crk are 
modified by altering levels of Abl, and vice versa. By fully characterizing Crk’s role in 
development, we can gain a better understanding of Crk’s role in cancer and other disease states 
and create better treatments for these conditions. 
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